Compare Johnson & Johnson (JNJ) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Block Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Johnson & Johnson is far larger — about 13.7× Block Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Block Inc for 78 Days on average.
| JNJ | XYZ | |
|---|---|---|
Market Cap | $618.09B | $45.20B |
Volume | 6,050,983 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $278.43 | $84.85 |
52-Week Low | $186.00 | $49.04 |
Typical Hold Time | 129 Days | 78 Days |
Enterprise Value | $646.37B | $40.10B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
XYZ trades at $75.21, down 1.13% on the day, with technical indicators showing bearish momentum near key support at $74. The company reported mixed Q3 2026 earnings with two beats and one miss, while revenue growth has slowed to 0.4% year-over-year in 2025. Analyst consensus remains strongly bullish with a $97.47 price target, representing 30% upside potential from current levels.
XYZ faces valuation concerns with a high P/E ratio of 134.34, though strong institutional support and expanding merchant partnerships provide growth catalysts. Key risks include declining net income margins and negative cash flow trends, requiring careful monitoring of upcoming Q3 2026 results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
